Biomarkers and diagnostics in heart failure

Published

Journal Article (Review)

Heart failure (HF) biomarkers have dramatically impacted the way HF patients are evaluated and managed. B-type natriuretic peptide (BNP) and N-terminal proBNP (NT-proBNP) are the gold standard biomarkers in determining the diagnosis and prognosis of HF, and studies on natriuretic peptide-guided HF management look promising. An array of additional biomarkers has emerged, each reflecting different pathophysiological processes in the development and progression of HF: myocardial insult, inflammation and remodeling. Novel biomarkers, such as mid-regional pro atrial natriuretic peptide (MR-proANP), mid-regional pro adrenomedullin (MR-proADM), highly sensitive troponins, soluble ST2 (sST2), growth differentiation factor (GDF)-15 and Galectin-3, show potential in determining prognosis beyond the established natriuretic peptides, but their role in the clinical care of the patient is still partially defined and more studies are needed. This article is part of a Special Issue entitled: Heart failure pathogenesis and emerging diagnostic and therapeutic interventions. © 2013 Elsevier B.V.

Full Text

Duke Authors

Cited Authors

  • Gaggin, HK; Januzzi, JL

Published Date

  • December 1, 2013

Published In

Volume / Issue

  • 1832 / 12

Start / End Page

  • 2442 - 2450

Electronic International Standard Serial Number (EISSN)

  • 1879-260X

International Standard Serial Number (ISSN)

  • 0925-4439

Digital Object Identifier (DOI)

  • 10.1016/j.bbadis.2012.12.014

Citation Source

  • Scopus